Performance & recovery · Prescription only
Sermorelin (High Dose)
A higher-dose sermorelin option for patients whose provider determines a standard starting dose is not sufficient, available after evaluation.
Treatment length is confirmed at checkout after your provider approves treatment.
Beginning treatment does not create a prescription. A US-licensed provider reviews your intake first, and an order is only filled if they determine treatment is appropriate for you.
Treatment details
- Medication
- Sermorelin (High Dose)
- Category
- Performance & recovery
- Access
- Available after a licensed-provider evaluation
- Fulfillment
- Compounded by a US-licensed compounding pharmacy
- FDA status
- Compounded — not FDA-approved
- Shipping
- Discreet, United States only
$219.00 is a placeholder price pending final confirmation. Van Peptides does not compound, manufacture, or dispense medication itself.
What it is
Sermorelin is a 29-amino-acid analog of growth-hormone-releasing hormone (GHRH), the shortest synthetic peptide fragment that retains full GHRH biological activity. It works upstream of growth hormone itself, prompting the pituitary to release its own GH rather than supplying GH directly (Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency, BioDrugs, DOI 10.2165/00063030-199912020-00007). A branded sermorelin product was previously FDA approved in the United States but has since been withdrawn from the market, so no FDA-approved sermorelin brand is currently available; sermorelin obtained through this pathway is a compounded preparation, not an FDA-approved drug product.
This high-dose option exists for situations where a provider, after reviewing your history and any prior response to a standard dose, determines a higher dose may be appropriate. It is not a self-selected upgrade. Sermorelin, at any dose, is available after a licensed-provider evaluation, and if a prescription is issued it is compounded through a US-licensed compounding pharmacy rather than manufactured or dispensed by Van Peptides.
Van Peptides connects patients with an independent network of US-licensed providers who evaluate whether sermorelin, and at what dose, fits your goals and medical history. We do not diagnose, prescribe, or dispense, and we do not employ the providers or the pharmacy that compounds any medication prescribed.
What the literature has explored
The dose-response relationship for GHRH analogs like sermorelin has been studied primarily in the context of diagnosing and treating growth hormone deficiency, where subcutaneous dosing at bedtime was shown to increase height velocity over sustained treatment periods in pediatric populations (BioDrugs review, DOI 10.2165/00063030-199912020-00007). Older pharmacology literature on GHRH-analog secretagogues has also examined how varying the dose changes the amplitude and duration of the resulting growth-hormone pulse, which is part of the rationale some providers cite when considering a higher-dose approach for adult patients (Stimulation of endogenous growth hormone secretion).
Most of the controlled trial data behind sermorelin comes from the pediatric growth-hormone-deficiency population studied under the now-withdrawn branded product, not from adult performance or recovery-focused use at higher doses. Extending that mechanism to adult goals is a reasonable area of clinical interest, but it has not been established with the same trial rigor, and individual results vary. A licensed provider is best positioned to weigh whether a higher dose makes sense for you specifically, based on your history and any labs or prior response.
We describe the mechanism and the diagnostic-era trial data because they are real and relevant, but we do not present them as proof of a specific outcome at any dose. Outcomes are individual, and that applies as much to a high-dose protocol as to a standard one.
How the telehealth path works
- Complete a short online intake.
- A US-licensed provider reviews your history and speaks with you if appropriate.
- If clinically appropriate, a prescription is issued and routed to a US-licensed compounding pharmacy.
- The medication ships discreetly in the US, with dispensing instructions from the pharmacy.
Van Peptides is a technology platform. It does not diagnose, prescribe, compound, or dispense. Each step above is carried out by an independent US-licensed provider or a US-licensed compounding pharmacy.
Common questions
What is Sermorelin (High Dose)?
It is a higher-dose version of sermorelin, a GHRH analog that prompts the pituitary to release growth hormone, offered for patients whose provider determines a standard dose is not the right fit.
Who is a candidate?
A US-licensed provider determines candidacy and dose based on your intake, history, and any prior response to sermorelin; it is available after a licensed-provider evaluation.
Is it FDA approved?
No. A branded sermorelin product was previously FDA approved but has been withdrawn from the US market, so no FDA-approved sermorelin brand currently exists. Compounded sermorelin, at any dose, is not FDA approved.
How is a high dose different from a standard dose?
The peptide and mechanism are the same; only the concentration or amount prescribed differs, and that decision rests with your provider, not with self-selection.
How is it dispensed?
If prescribed, compounded sermorelin is dispensed through a US-licensed compounding pharmacy and shipped to you.
What does it cost?
Placeholder plan pricing is $149 monthly, $399 for a three-month plan, and $749 for a six-month plan. Final pricing will be confirmed before this page goes live.
How is my privacy protected?
Your health information is handled under our HIPAA Notice of Privacy Practices.
What if it isn’t right for me?
If a provider determines a high dose, or sermorelin generally, is not appropriate for you, they will explain their reasoning and discuss alternatives as part of your evaluation.